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Abstract
The umbilical cord blood (UCB) can be used for early detection of neonatal diseases. The 
UCB can be used for early detection of neonatal diseases. Establishing reference intervals 
is essential for appropriate interpretation of results of laboratory tests using UCB and for 
correct medical decisions of pediatricians and neonatologists. The use of proper refer‐
ence intervals provides reliable information to pediatricians and neonatologists; thus, 
they could make correct medical decisions for neonates. This chapter discussed refer‐
ence intervals of platelets, lymphocytes, and cardiac biomarkers in UCB according to the 
Clinical Laboratory Standards Institute guidelines. Except iatrogenic anemia, thrombo‐
cytopenia is the most common hematologic abnormality in neonates. Immature platelet 
fraction is a novel parameter to estimate megakaryopoiesis and can be useful to under‐
stand the mechanism of thrombocytopenia, platelet destruction or bone marrow failure, 
in neonates. Lymphocyte counts, T cell and B cell, can reflect status of immune system 
in fetus and neonates. Especially Tregs in UCB may contribute to maintain the immune 
homeostasis in the feto‐maternal relationship, and the presence of Tregs would be essen‐
tial to prevent immune dysregulation in fetus and neonates. Congenital heart disease or 
defect is the most common birth defect in newborns. Cardiac biomarkers are essential to 
evaluate heart function and to give information of myocardial injury, necrosis, or myo‐
cardial stretch. There are no current guidelines for their routine use in children.
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1. Introduction
Obtaining admission laboratory studies is necessary to provide appropriate neonatal care. 
As a general rule, the blood drawn for laboratory testing should not exceed 5% of the total 
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blood volume per draw; thus, in neonates and infants, a less‐than‐optimal amount of blood 
may be available for testing. Approximately 1.5 – 4 mL of blood drawn for admission blood 
test may cause iatrogenic anemia to neonates especially in extremely low birth weight infants 
[1, 2]. Umbilical cord blood (UCB) is remained blood in the placenta and attached umbilical 
cord after the birth of baby. Several studies suggest that UCB could be an alternative source 
for admission of blood tests in neonates [1, 3, 4]. Especially, very low birth weight infants who 
typically have greater phlebotomy blood loss on the first day of life than any other day during 
their hospitalization would benefit most from admission laboratory studies being obtained 
from UCB [5, 6].
At birth, full‐term newborns show relative polycythemia, macrocytosis, and marked poly‐
chromasia with nucleated red blood cells (RBCs) [7, 8]. The red cell distribution width 
(RDW) is elevated, showing anisocytosis, compared with adult standards. Full‐term new‐
borns have a high white blood cell (WBC) count with relative transient neutrophilia at 
birth while soon after birth, neutrophils gradually decrease and lymphocytes become 
major population in neonate's peripheral blood. This neutrophilia may arise from bone 
marrow mobilization under stress during labor, and these WBCs show shift‐to‐left neu‐
trophils such as metamyelocytes, myelocytes, and even circulating blasts [9, 10]. The 
platelet counts are similar to the older children and adults. Neonatal thrombocytopenia is 
defined as a platelet count less than 150 × 109/L in any neonate of a viable gestational age. 
Thrombocytopenia is one of the most common hematological abnormalities except iatro‐
genic anemia in neonates [11, 12].
During the pregnancy, human placenta forms an imperfect barrier, allowing bidirectional 
passage of soluble antigens and cells between a mother and a baby without any mixing 
between the two blood supplies [13]. This results in the presence of fetal cells in the maternal 
circulation, known as fetal microchimerism, and maternal cells in the fetal circulation, known 
as maternal microchimerism [14]. Maternal microchimerism was first described in 1963 by 
Rajendra G. Desai who identified maternal leukocytes and platelets in UCB [15]. This bidirec‐
tional trafficking of cells begins at seven to 16 weeks, increases steadily after 24 weeks, and 
reaches a peak at parturition [16]. At delivery, maternal microchimerism has been reported 
in 42% of normal pregnancies [13]. For this, microchimerism does not occur in all pregnan‐
cies, altered maternal‐fetal bidirectional passage has been associated with disruption of the 
feto‐maternal interface, and the biologic role of this bidirectional passage is unclear. This pas‐
sage is implicated in development of the fetal immune system [17]. Substantial numbers of 
maternal cells cross the placenta to reside in fetal lymph nodes, inducing the immune system, 
the development of CD4+CD25highFOXP3+ regulatory T cells (Tregs), which suppresses fetal 
antimaternal immunity.
UCB is a rich source of hematopoietic cells or precursors to blood cells. Since the first UCB 
stem cell transplantation in 1988 to treat a child with Fanconi’s anemia, UCB has been used as 
an important source of hematopoietic stem cell transplantation [18]. UCB could be collected at 
birth without any harm to the newborn infant. UCB cells have many theoretical advantages as 
grafts for stem cell transplantation because of the immaturity of newborn cells and immatu‐
rity of the immune system at birth. These properties should decrease the alloreactive potential 
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of the lymphocytes and should reduce the incidence and severity of graft‐versus‐host disease 
after human leukocyte antigen (HLA) ‐matched or HLA‐mismatched transplantation [19]. 
The recovery rate of colony‐forming unit correlated significantly with platelets as well as 
leukocytes, RBCs, mononuclear cells, CD34+ leukocytes, and viable leukocytes [20]. Detection 
of abnormal levels of platelets, leukocytes, RBCs, mononuclear cells, CD34+ leukocytes, and 
viable leukocytes could be one of UCB screening tests available.
The interpretation of results of laboratory tests includes the comparison between the reported 
values versus documented reference intervals. The reference intervals are defined as values 
obtained by measurement of a particular type of quantity on a reference individual who 
selected for testing on the basis of well‐defined criteria who is considered being in healthy 
state from general population [21]. For these reasons, establishment of reference intervals 
for blood tests such as complete blood counts and biomarkers in UCB is crucial for clinical 
laboratory tests. We discuss the reference intervals of platelets, lymphocytes, and cardiac bio‐
markers in UCB.
2. Establishing reference intervals in umbilical cord blood
The production of health‐associated reference values must be implemented in accordance 
with a well‐defined protocol. The Clinical Laboratory Standards Institute (CLSI) offers 
a protocol for determining reference intervals that meet the minimum requirements for 
reliability and usefulness related to quantitative clinical laboratory tests [21]. The CLSI 
suggested a protocol outline for obtaining reference values and establishing reference 
intervals. First, researchers should establish a list of analytical interferences and sources 
of biological variability from medical and scientific literatures. Then, they must establish 
selection and partition criteria and an appropriate questionnaire designed to reveal these 
criteria in the potential reference individuals. An appropriate written consent should be 
signed by legal guardians of neonates. Researchers have to categorize the potential refer‐
ence individuals based on the results of questionnaire and health assessments and exclude 
individuals based on the exclusion criteria. For UCB, gestational age, birth weight, mater‐
nal age, maternal health, and maternal history of medical, smoking, and alcohol consump‐
tion are important.
The reference interval is defined as the internal between and including two numbers, an upper 
and lower reference limit, which are estimated to enclose a specified percentage (usually 95%). 
For most analytes, the lower and upper reference limits are estimated as the 2.5th and 97.5th 
percentiles of the distribution of test results for reference populations. To decide on an appro‐
priate number of reference individuals, in consideration of desire confidence limits, the CLSI 
suggests that a minimum of 120 reference values for 90% confidence limits, 146 observations 
for 95% confidence limits, and 210 reference values for 99% confidence limits. It is necessary 
to define whether the sample should be arterial or venous UCB in a manner consistent with 
the routine practice for patient specimens. Inspection of the reference value data, preparing 
a histogram, and identifying possible data errors and/or outliers are essential to evaluate the 
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distribution of data. Furthermore, partitioning into subclasses for separate reference intervals 
should be considered if appropriate according to gestational age, gender of neonates, and 
maternal age.
For difficulties of sample obtaining, it is not easy to establish reference intervals of parameters 
for neonates according to the CLSI guideline. Even published reference intervals using neo‐
nates’ peripheral blood or UCB are very useful and informative for clinical laboratory tests, 
physicians should keep in mind that some of published reference intervals did not satisfy the 
CLSI guideline for sample collection.
3. Platelets
The first morphologically visible platelets appear in the fetal circulation at seven to nine 
weeks, and the platelet counts reach adult levels before 18th gestational week [2, 22]. The 
intrauterine thrombocytopenia could diagnose through fetal blood sampling after 18th ges‐
tational week [2]. The platelet counts are constant at birth and in neonatal period and com‐
patible to the count in adult. Neonatal thrombocytopenia has been defined traditionally 
as a platelet count less than 150 × 109/L. This definition was challenged by recent studies. 
Large‐scale study presented that platelet counts of preterm neonates born before 35 weeks 
gestation were significantly lower than those that were of late‐preterm and preterm infants 
[23]. Wasiluk [24] reported the platelet count is found to be decreased in preterm and late‐
preterm newborns. The platelet counts were increasing with completed weeks of gestation 
and birth weight. Decreased platelet count in preterm could be considered as immaturity 
of thrombopoiesis and impaired process of megakaryopoiesis characterized by the rapid 
proliferation of megakaryocyte precursors and full cytoplasmic maturation of megakaryo‐
cytes leading to the production of high number of platelets. Levels of thrombopoietin and 
reticulated platelets (immature platelet fraction, IPF) could reveal the megakaryopoiesis of 
fetus and neonates.
Except iatrogenic anemia, thrombocytopenia is the most common hematological abnormal‐
ity in neonates [11]. Incidence of thrombocytopenia is 1–5% in newborns at birth [25–27]. 
Thrombocytopenia may be caused by feto‐maternal and neonatal conditions such as impaired 
platelet production, consumption and sequestration, and combined mechanisms [28–31]. 
Platelet transfusion is associated with several risks including infection, transfusion‐related 
acute lung injury, transfusion‐associated circulatory overload, alloimmunization, allergic 
reaction, and other complications. Therefore, platelet should be given when clearly clini‐
cally indicated [31, 32]. Reference values for normal platelet counts, especially lower limit, 
are important to diagnose thrombocytopenia. In particular, there is a need for supplementary 
parameters in order to evaluate the megakaryopoiesis and bleeding risk [31].
IPF is newly released from fetal liver or the bone marrow and containing high amount of 
ribonucleic acid (RNA). Thiazole orange, a fluorescent dye, is characterized by binding to 
nucleic acid, particularly RNA, and flow cytometric analysis of platelets after staining with 
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thiazole orange reflects the activity of megakaryopoiesis in the bone marrow [33]. Measuring 
IPF of the systemic circulation is a novel parameter to estimate the megakaryopoiesis and 
can be useful to recognize quickly as having platelet destruction or bone marrow failure in 
a neonate with low platelet count [34]. Measuring IPF may potentially avoid the need for 
bone marrow examination. Increased IPF% or normal IPF number (IPF#) is considered in the 
case of platelet consumption in thrombocytopenia, whereas normal or decreased IPF% and 
IPF# is considered in the case of bone marrow failure in thrombocytopenia. Today, IPF can 
be measured on fully automated routine hematology analyzers (XE‐2100 and XN modular 
system; Sysmex, Kobe, Japan) [35]. Establishment of reference intervals for platelet and IPF 
in neonates is essential for diagnosis of neonatal thrombocytopenia, for facilitating the clini‐
cal usefulness of IPF, and for clear indication of transfusion. Table 1 shows the comparison 
of studies measuring IPF in healthy subjects. The new automated hematology analyzer, XN 
modular system, demonstrated remarkable higher and broader reference intervals for plate‐
lets and IPF compared with XE‐2100 [36]. For these differences, clinical laboratories should 
establish or verify reference intervals for platelets and IPF according to their own instrument.
4. Lymphocytes
Lymphocytes in UCB are naïve and immature, are enriched in double‐negative CD3+ cells, 
and produce fewer cytokines [19]. Lymphocyte counts, T cell and B cell, can reflect status of 
immune system in fetus and neonates. B‐ and/or T‐cell lymphocytopenia could be noted in 
some viral infection but also in Wiskott‐Aldrich syndrome, X‐linked  agammaglobulinemia, 
Study Gestational 
age (week)
Number of 
participants
Platelet 
counts  
(×109/L)
Parameter Method or 
instruments
RP% or IPF% Absolute RP 
or IPF counts 
(×109/L)
[67] 36 39 246 ± 65 RP Flow 
cytometry
4 ± 2.4% 10.5 ± 8.7
[68] 28 ± 2.5 37 150–450 RP Flow 
cytometry
2.7 ± 1.6% NA
[69] 38–41 72 316.96 ± 60.76 RP Flow 
cytometry
1.65 ± 0.95%
[70] 36.3 ± 3.7 456 150–450 IPF XE‐2100, 
Sysmex
4.3 (95% CI 
0.7–7.9)
NA
[34] 39.3 
(38.0–41.6)
133 191–392† IPF XE‐2100, 
Sysmex
0.7–3.8† 1.94–9.69†
[36] 39.0 
(38.0–41.3)
140 174–405† IPF XN, Sysmex 1.0–4.4† 2.9–12.8†
IPF, immature platelets; NA, not available; RP, reticulated platelets.
† Reference interval.
Note: Data were expressed as mean ± standard deviation, range, or median (range).
Table 1. Comparison of studies measuring reticulated platelets and immature platelet fraction in healthy newborns.
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and severe combined immunodeficiency [37–40]. To define abnormality of lymphocyte 
counts, quantitation of the lymphocytes and their subtypes with flow cytometry and estab‐
lishment of reference interval are necessary.
Circulating T cells in the fetus and neonate are fundamentally different from naïve adult 
T cells such as containing high concentration of T‐cell receptor excision circles (TRECs), 
high cell turnover, increased susceptibility to apoptosis, and presence of CD25+ regulatory 
T lymphocytes (Tregs), and so on [41]. Natural Tregs originate in the thymus and are specific 
for self‐antigens presented by thymic epithelial cells [42]. Maternal cells commonly cross 
the placenta and engraft into fetal circulation and tissues in uterus, resulting in maternal 
microchimerism [17, 43]. Naturally acquired microchimerism can contribute to autoimmune 
diseases. In particular, maternal microchimerism has been studied in systemic sclerosis, der‐
matomyositis, and neonatal lupus [43]. Especially, Tregs in UCB may contribute to maintain 
the immune homeostasis in the feto‐maternal relationship, and the presence of Tregs would 
be essential to prevent immune dysregulation in fetus and neonates [17, 44]. Fetal Tregs 
are known to regulate fetal immune responses against noninherited maternal alloantigens. 
During labor, neonatal immune system faces big challenge. The tolerogenic immune state of 
the semi‐allogeneic fetus should switch over to prevent potentially damaging inflammation 
or infection. In immunosuppressive state, several cells such as helper T cells with a specific 
cytokine profile, neutrophilic myeloid‐derived suppressor cells, erythroid CD71+ cells, and 
Tregs are potential mediators [45, 46].
Infection of newborn and infants is a major healthcare challenge with global mortality in excess 
of one million lives especially in very low‐birth‐weight preterm infants [47]. Preterm infants 
are highly susceptible to invasive infections, which are leading causes of mortality and long‐
term morbidity. Treg levels and gestational age inversely correlated in several studies [48–50]. 
Preterm infants have higher Treg levels than full‐term newborns. Tregs inhibit antimicrobial 
immune responses. The T cell immune response in preterm infants is supposed to be dys‐
regulated and affected by prenatal factors including intrauterine inflammation and maternal 
characteristics. This dysregulation of T cell immunity could lead to ineffective clearance of 
pathogens [49]. Tregs have two populations (CD31+ and CD31‐), and the ratio alteration of these 
populations is associated with different intra‐ and/or extra‐uterine milieu. The CD31‐ Treg lev‐
els are significantly higher in UCB of preterm pregnancies associated with inflammation and 
prenatal lipopolysaccharide exposure. The alteration of homeostatic composition of Tregs sub‐
sets related to reduced de novo generation of recent thymic emigrants. Tregs may contribute 
to premature delivery, and vice versa. Early‐onset septic infants have significantly higher Treg 
frequencies than infants without early‐onset sepsis. The increased Treg level may cause an 
uncontrolled immunosuppression and therefore results in an increased risk of sepsis for the 
preterm infants especially for the most vulnerable very low‐birth‐weight infants (Figure 1) [46].
In spite of the growing attention on the importance of Tregs in UCB and neonates, the dis‐
tribution of Tregs in normal UCB or healthy neonates was not well‐known. Table 2 showed 
the comparison of studies measuring lymphocyte subsets and Tregs in healthy subjects. Each 
study showed different values for lymphocyte subsets and Tregs. For these  differences, clinical 
laboratories should establish or verify reference intervals for lymphocyte subsets and Tregs.
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Figure 1. The frequency of regulatory T cells (Tregs) is higher in preterm infants than in term infants. Box‐plots [median, 
interquartile range (IQR), 95% confidence interval (CI)] describe the frequencies of Tregs across groups of different 
gestational age. Adapted from [46] with permission of John Wiley and Sons, Inc.
Study Gestational 
age (week)
Number of 
participants
Helper T cells 
(CD3+/CD4+, %)
Cytotoxic T 
cells (CD3+/
CD8+, %)
B cells (CD19+, 
%)
NK cells 
(CD3‐/
CD16+/
CD56+, %)
Regulatory T 
cells (CD4+/
CD25high/
FOXP3+, %)
[71] Healthy 
full‐term
98 46.7 (40.2–61.9) 16.3 
(14.3–21.3)
11.5 (7.6–15.5) NA 5.2 (3.5–7.0)¶
[72] NA 22 NA NA 17.2 (13.2–25.4) NA NA
[73] NA 38 44 (34–57)‡ 17 (11–30)‡ 16 (9–23)‡ 16 (6–28)‡ NA
[44] 38.0–41.3 120 15.40–70.06† 9.65–34.28† 4.50–29.59† 1.42–28.03† 0.35–9.07†
[74] ≥35 18 41 (26–62) 14 (5–37) 10 (3–30) 22 (8–62) 7 (4–13)¶
[75] NA 53 28.9 (11.4–40.3)‡ 11.8 
(6.1–18.3)
15.2 (9.3–22.0) 18.2 
(8.6–28.2)
16.7 
(12.3–23.8)§
† Reference interval.
‡ Median values with 10th and 90th percentiles.
§ CD4+/CD25+.
¶ CD4+/CD25+/CD127‐.
Note: Data were expressed as mean ± standard deviation, range, or median (range).
Table 2. Comparision of studies measuring lymphocyte subsets and Tregs in healthy subjects.
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5. Cardiac biomarkers
Congenital heart disease or defect (CHD) is the most common birth defect in newborns [51]. 
Critical CHDs require intervention or surgery in the first year of life. Echocardiography is a 
definitive diagnostic tool of CHD and provides hemodynamic and anatomic information of 
heart. Twenty‐five to 30% of children, however, with critical CHD are not detected by fetal 
echocardiography until after discharge from the birth hospitalization [52]. Cardiac biomarkers 
are essential to evaluate heart function and give information of myocardial injury, necrosis, or 
myocardial stretch. Concentrations of cardiac troponins, troponin I (TnI) or troponin T (TnT), 
are elevated in myocardial necrosis and myocardial infarction. Troponins are also increased 
in patients with heart failure and myocarditis. Elevated concentration of brain‐type natriuretic 
peptides (BNP) or N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) is related to myo‐
cardial stretch and left ventricular dysfunction and can be used for screening and prognosis 
of heart failure (HF) [53, 54]. Suppression of tumorigenicity 2 (ST2), a member of the inter‐
leukin (IL)‐1 receptor family, has two isoforms: transmembrane ST2 and soluble ST2 (sST2). 
IL‐33 reduces fibrosis and hypertrophy of myocardium, and preserves ventricular function. 
The sST2 plays a role as a decoy receptor of IL‐33, and binding of IL‐33 and sST2 inhibits the 
beneficial and protective effect of IL‐33 on the heart. The concentration of sST2 is elevated in 
patients with HF and is also associated with the prognosis of acute and chronic HF [55].
Many studies reported that NT‐proBNP or BNP was elevated in peripheral blood or UCB with 
neonates with CHD [56]. A few studies presented the distribution of TnI or TnT in neonates 
or UCB [57–60]. The distribution and association of sST2 with CHD have not been investi‐
gated yet. There are no current guidelines for their routine use in children. The levels of NT‐
proBNP were significantly increased in UCB of neonates with CHD compared with that in 
the UCB of control group. In addition, the levels of NT‐proBNP were significantly increased 
in the neonates with tight ventricular outflow tract obstruction without a ventricular septal 
defect compared with that in the other groups (Figure 2). Moreover, there was significant dif‐
ference between survivors and non‐survivors within one‐year of birth [61]. Hydrops fetalis is 
fluid collection in multiple body compartments in fetus because of immune or non‐immune 
mechanism. Congestive heart failure or cardiac dysfunction has been described as one of the 
major mechanisms for nonimmune hydrops fetalis. The levels of NT‐proBNP in cases with 
hydrops of cardiac origin were higher than those in cases with hydrops of non‐cardiac origin. 
However, levels of TnT did not differ though the causes of hydrops fetalis [62].
The only one study reported 97.5th percentile upper reference limit of NT‐proBNP and TnT from 
healthy neonates, according to the CLSI guideline [21, 63]. In uterus, hemodynamics between pla‐
centa and fetal heart can vary with gestational age [64, 65], and reference intervals for cardiac bio‐
markers in neonates could be different from those in adults. Therefore, establishment of reference 
intervals is necessary to use cardiac biomarkers in neonates. Table 3 showed the comparison of 
sST2, NT‐proBNP, high sensitive TnI, and high sensitive TnT in UCB and adults. For these differ‐
ences between laboratory tests results in UCB and adults, clinical laboratories should establish or 
verify reference intervals for cardiac biomarkers in UCB. Kim H et al. [66] reported that levels of 
sST2, NT‐proBNP, and high sensitive TnT in UCB were significantly higher than those in adults.
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Figure 2. The distribution of NT‐proBNP levels in the umbilical cord blood of neonates with cardiac malformations 
according to the type. Abbreviations: HLHS, hypoplastic left heart syndrome; NT‐proBNP, N‐terminal pro‐brain 
natriuretic peptide; RVOTO, right ventricular outflow tract obstruction; TOF, tetralogy of Fallot. Adapted from [61] with 
permission of Springer International Publishing AG.
97.5th percentile upper reference 
limit in UCB from healthy, full‐term 
neonates (90% CI)
Medical decision point for adults 
(reference)
sST2 (ng/mL) 59.9 (52.7–62.2) 35 [76]
NT‐proBNP (pg/mL) 1415.3 (1070.0–2198.0) 300 [77], 125 [78]
hs‐TnI (pg/mL) 27.8 (21.v1–30.4) 26.2 [79]
hs‐TnT (pg/mL) 86.5 (68.0–99.0) 14 [80]
sST2, soluble suppression of tumorigenicity 2; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; hs‐TnI, high 
sensitive troponin I; hs‐TnT, high sensitive troponin T; UCB, umbilical cord blood.
Table 3. Comparison of sST2, NT‐proBNP, high sensitive TnI, and high sensitive TnT in UCB and adults. Adapted from 
[66] with permission of Walter de Gruyter GmbH.
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